Relative Contributions of Radiation and Cisplatin-Based Chemotherapy to Sensorineural Hearing Loss in Head-and-Neck Cancer Patients

Hitchcock, Ying J.; Tward, Jonathan D.; Szabó, Anikó; Bentz, Brandon G.; Shrieve, Dennis C.

doi:10.1016/j.ijrobp.2008.05.040

Cited by 101 publications

(79 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our short-term study further confirmed that the severity of the SNHL is strongly related to the irradiation-absorbed dose-volume; however, there are other studies showing the effects of radiation as well as chemoradiotherapy regime on the hearing loss [6,7]. There are several variables that could have an effect on the risk of developing hearing loss side effects.…”

Section: Discussionsupporting

confidence: 78%

Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy

et al. 2015

View full text Add to dashboard Cite

The aim of this study was to investigate the risk of sensorineural hearing loss (SNHL) and the relationship between SNHL and radiation dose to the cochlea and frequency range of hearing loss in patients with head and neck cancer. Pure tone audiometry at 250-12,000 Hz was performed on 29 patients diagnosed with head and neck tumours who were treated with 3-dimensional conformal radiation therapy and followed up for 6 months. Paired t test indicated that the mean air conduction threshold before and after radiotherapy was significantly different (paired t test, p < 0.001). SNHL was observed in 15 patients (51 %) according to CTCAE. SNHL increased to 77 % in patients who had received at least five concurrent cisplatin cycles. There was an increased risk of SNHL for ears receiving a mean dose of 5000 cGy compared to those receiving <5000 cGy. SNHL was more severe at higher frequencies of pure tone audiometry in patients with cisplatin-based chemoradiation. The ototoxicity effect of radiation and cisplatin must be considered in the treatment of head and neck tumours. Increasing the dose of cisplatin, radiation dose of cochlea and follow-up interval time may result in increasing severity and frequency of hearing loss incidences. However, characteristic of radiation-induced SNHL seems to be different from chemoradiation-induced SNHL.

show abstract

Section: Discussionsupporting

confidence: 78%

Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Chan et al found that a D mean cochlea of below 47 Gy resulted in fewer than 15% of patients developing severe high-frequency sensorineural hearing loss (16). Investigators from the University of Utah found that the threshold for hearing loss with cisplatin-based chemotherapy and RT was 10 Gy based on a mathematical model; for cochlea receiving 10 Gy, hearing loss at 8 KHz was 21.5 AE 9.5 dB, whereas for 40 Gy, it was 38.4 dB AE 18.9 dB (18).…”

Section: Discussionmentioning

confidence: 99%

Ototoxicity After Intensity-Modulated Radiation Therapy and Cisplatin-Based Chemotherapy in Children With Medulloblastoma

Paulino

Lobo

Teh

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Given both chemotherapy and RT have hair cell toxicity, radiation dose constraints and chemotherapy dose intensity should be considered. High-frequency SNHL was found profoundly damaged in head and neck cancers patients who received concomitant cisplatin with doses of 100 mg/ m2/3 weeks compared to 40 mg/m2/1 weekly (Hitchcock et al, 2009). The threshold cochlear dose for hearing loss with CDDP-based chemotherapy and RT was estimated to be 10 Gy (Hitchcock et al, 2009), which is far from the curative dose however.…”

Section: Concurrent Chemotherapy Selectionmentioning

confidence: 94%

“…High-frequency SNHL was found profoundly damaged in head and neck cancers patients who received concomitant cisplatin with doses of 100 mg/ m2/3 weeks compared to 40 mg/m2/1 weekly (Hitchcock et al, 2009). The threshold cochlear dose for hearing loss with CDDP-based chemotherapy and RT was estimated to be 10 Gy (Hitchcock et al, 2009), which is far from the curative dose however. In the chemo-radiotherapy treatment for NPC, the incidence of high-frequency SNHL is significant higher in patients treated with CDDP than those with carboplatin (Petsuksiri et al, 2011).…”

Section: Concurrent Chemotherapy Selectionmentioning

confidence: 94%

Radiation-induced Cochlea Hair Cell Death: Mechanisms and Protection

Tan

Du²,

Ren³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Relative Contributions of Radiation and Cisplatin-Based Chemotherapy to Sensorineural Hearing Loss in Head-and-Neck Cancer Patients

Cited by 101 publications

References 25 publications

Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy

Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy

Ototoxicity After Intensity-Modulated Radiation Therapy and Cisplatin-Based Chemotherapy in Children With Medulloblastoma

Radiation-induced Cochlea Hair Cell Death: Mechanisms and Protection

Contact Info

Product

Resources

About